Hepion pharmaceuticals announces exercise of warrants for approximately $2.0 million aggregate gross proceeds

Edison, n.j., feb. 16, 2024 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding series b common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of hepion common stock for gross proceeds to the company of approximately $2.0 million.
HEPA Ratings Summary
HEPA Quant Ranking